Precigen, Inc. (PGEN)

NASDAQ: PGEN · Real-Time Price · USD
0.848
-0.002 (-0.28%)
Oct 8, 2024, 3:09 PM EDT - Market open
-0.28%
Market Cap 247.67M
Revenue (ttm) 4.39M
Net Income (ttm) -135.38M
Shares Out 288.06M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 571,204
Open 0.853
Previous Close 0.850
Day's Range 0.833 - 0.869
52-Week Range 0.833 - 1.930
Beta 1.66
Analysts Buy
Price Target 7.00 (+714.14%)
Earnings Date Nov 7, 2024

About PGEN

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gen... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 202
Stock Exchange NASDAQ
Ticker Symbol PGEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for PGEN stock is "Buy." The 12-month stock price forecast is $7.0, which is an increase of 714.14% from the latest price.

Price Target
$7.0
(714.14% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

GERMANTOWN, Md. , Sept. 16, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o...

21 days ago - PRNewsWire

Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Thursday.

Other symbols: GGRTITN
7 weeks ago - Benzinga

Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript

Precigen, Inc. (NASDAQ:PGEN) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Steven Harasym - VP, IR Helen Sabzevari - President & CEO Harry Thomasian - CFO Phil Tenn...

7 weeks ago - Seeking Alpha

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

– In June 2024, the Company announced groundbreaking pivotal study data for PRGN-2012 gene therapy at the 2024 ASCO annual meeting in which more than half of RRP patients achieved Complete Response – ...

7 weeks ago - PRNewsWire

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

GERMANTOWN, Md. , Aug. 9, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of ...

2 months ago - PRNewsWire

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

GERMANTOWN, Md. , Aug. 7, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 35,294,118 shares of its common stock at a public offerin...

2 months ago - PRNewsWire

Precigen Announces Proposed $30 Million Public Offering of Common Stock

GERMANTOWN, Md. , Aug. 6, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced a $30.0 million underwritten public offering of its common stock.

2 months ago - PRNewsWire

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

– PRGN-2012 is on track for a rolling BLA submission under an accelerated approval pathway; patient enrollment initiated in the confirmatory clinical trial – GERMANTOWN, Md. , Aug. 6, 2024 /PRNewswire...

2 months ago - PRNewsWire

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

–  Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis  – GERMANTOWN, Md. , July 23, 2024 /PRNewsw...

2 months ago - PRNewsWire

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

–   Phase 1/2 pivotal study met the primary safety and efficacy endpoints – –   51% (18 out of 35) of patients achieved Complete Response, requiring no surgeries after treatment with PRGN-2012; comple...

4 months ago - PRNewsWire

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

GERMANTOWN, Md. , May 23, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of ...

4 months ago - PRNewsWire

Precigen Reports First Quarter 2024 Financial Results and Business Updates

–   Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presentation...

5 months ago - PRNewsWire

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

GERMANTOWN, Md. , May 8, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of p...

5 months ago - PRNewsWire

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

GERMANTOWN, Md. , April 24, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o...

5 months ago - PRNewsWire

Actym Therapeutics Appoints Thomas Smart as CEO

BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.

Other symbols: ANABXOMA
5 months ago - PRNewsWire

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

–  Inaugural multi-stakeholder event on June 11th (6/11)  will raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials – –   RRP is a rare, HPV...

6 months ago - PRNewsWire

Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript

Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript

7 months ago - Seeking Alpha

Precigen Reports Full Year 2023 Financial Results and Business Updates

–   Significant progress made in the development of the PRGN-2012 AdenoVerse immunotherapy for the treatment of RRP; Precigen plans to submit a BLA under an accelerated approval pathway in the second ...

7 months ago - PRNewsWire

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

GERMANTOWN, Md. , March 12, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives o...

7 months ago - PRNewsWire

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

GERMANTOWN, Md. , March 5, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of...

7 months ago - PRNewsWire

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GERMANTOWN, Md. , Feb. 6, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of ...

8 months ago - PRNewsWire

Precigen: RRP Targeting With AdenoVerse Technology Platform

FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA fi...

9 months ago - Seeking Alpha

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

– Designation is an important step toward bringing this potentially life-changing therapy to European patients – – EU Orphan Drug Designation is the first regulatory designation for a gorilla adenovec...

9 months ago - PRNewsWire

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

–   PRGN-2012 Phase 2 pivotal study data in RRP is anticipated in the second quarter of 2024; the Company plans to submit a BLA under an accelerated approval pathway in the second half of 2024; commer...

9 months ago - PRNewsWire

Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md., Dec. 18, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of ...

10 months ago - PRNewsWire